Biphasic effects of angiotensin II and receptor antagonism on aggregability and protein kinase C phosphorylation in human platelets

Thrombosis and Haemostasis

Volumn 94, Issue 5, 2005, Pages 1012-1018

  Utsugisawa, Kimiaki ^a   Kizawa, Hideki ^a   Nagane, Yuriko ^a   Kondoh, Ryushi ^a   Iwa, Yoko ^a   Akutsu, Hitomi ^a   Tohgi, Hideo ^a   Terayama, Yasuo ^a  

^a IWATE MEDICAL UNIVERSITY   (Japan)

Author keywords

Angiotensin II; AT I receptor; Platelet aggregation; Protein kinase C; Sartan

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CANDESARTAN; COLLAGEN; ISOENZYME; PROTEIN KINASE C; PROTEIN KINASE C ALPHA; PROTEIN KINASE C BETA; RECEPTOR SUBTYPE; VALSARTAN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; HYPERTENSION; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STROKE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOSIS;

ADULT; AGED; ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZIMIDAZOLES; BLOOD PLATELETS; FEMALE; HUMANS; IMIDAZOLES; ISOENZYMES; MALE; MIDDLE AGED; PHOSPHORYLATION; PLATELET AGGREGATION; PROTEIN KINASE C; PYRIDINES; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; TETRAZOLES; VALINE; VASOCONSTRICTOR AGENTS;

EID: 27844543816     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH05-02-0125     Document Type: Article

References (31)

1. Ito H, Takemori K, Suzuki T Role of angiotensin II type 1 receptor in the leucocytes and endothelial cells of brain microvessels in the pathogenesis of hypertensive cerebral injury. J Hypertension 2001; 19: 591-7.
2. Ito T, Yumakawa H, Bregonzio C et al. Protection against ischemia and improvement of cerebral blood flow in genetically hypertensive rats by chronic pretreatment with an angiotensin II AT1 antagonist. Stroke 2002; 33: 2297-303.
3. Nishimura Y, Ito T, Saavedra JM. Angiotensin II AT1 blockade normalizes cerebrovascular autoregulation and reduces cerebral ischemia in spontaneously hypertensive rats. Stroke 2000; 31: 2478-86.
4. 1 receptor inhibition. J Cereb Blood Flow Metab 2003; 23: 371-80.
5. Lorell BH. Role of angiotensin AT1 and AT2 receptors in cardiac hypertrophy and disease. Am J Cardiol 1999; 83: 48H-42H.
6. Dai W-J, Funk A, Herdegen T et al. Blockade of central angiotensin AT1 receptors improves neurological outcome and reduces expression of AP-1 transcription factors after focal brain ischemia in rats. Stroke 1999; 30: 2391-9.
7. WaltherT, Olah L, Harms C et al. Ischemic injury in experimental stroke depends on angiotensin II. FASEB J 2002; 16: 169-76.
8. Utsugisawa K, Nagane Y, Utsugisawa T et al. Candesartan prevents angiotensin II-induced facilitation of hypoxic neuronal damage through PKCδ inhibition. Mol Brain Res 2005; 135: 134-40.
9. Ding Y-A, MacIntire E, Kenyon CJ et al. Angiotensin II effects on platelet function. J Hypertension 1985; 3 (suppl 3): S251-S253.
10. Montón M, Jiménez A, Núñez A et al. Comparative effects of angiotensin II AT-1-type receptor antagonists in vitro on human platelet activation. J Cardiovasc Pharmacol 2000; 35: 906-13.
11. 2+ and phorbol ester stimulate platelet aggregation and secretion synergistically through protein kinase C. Biochem J 1988; 255: 309-18.
12. Gerrard JM, Beattie LL, Park J et al. A role for protein kinase C in the membrane fusion necessary for platelet granule secretion. Blood 1989; 74: 2405-13.
13. 2+ and protein kinase C is the major factor in determining the level of secretion from human platelets. Biochem J 1993; 289: 277-82.
14. Pulcinelli FM, Ashby B, Gazzaniga PP et al. Protein kinase C activation is not a key step in ADP-mediated exposure of fibrinogen receptors on human platelets. FEBS lett 1995; 364: 87-90.
15. Toullec D, Pianetti P, Coste H et al. The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C. J Biol Chem 1991; 266: 15771-81.
16. Crosby D, Poole AW. Physical and functional interaction between protein kinase Cδ and Fyn tyrosine kina-se in human platelets. J Biol Chem 2003; 278: 24533-41.
17. Tohgi H, Takahashi H, Kashiwaya M et al. Effect of plasma fibrinogen concentration on inhibition of platelet aggregation after ticlopidine compared with aspirin. Stroke 1994; 25: 2017-21.
18. Toligi H, Takahashi H, Watanabe K et al. Development of large platelet aggregates from small aggregates as determined by laser-light scattering: effects of aggregant concentration and antiplatelet medication. Thromb Haemostasis 1996; 75: 838-43.
19. Satoh K, Ozaki Y, Qi R et al. Factors that affect the size of platelet aggregates in epinephrine-induced activation: a study using the particle counting method based upon light scattering. Thromb Res 1996; 81: 515-23.
20. Serebruany VL, Maiinin Al, Lowry DR et al. Effects of valsartan and valeryl 4-hydroxy valsartan on human platelets: a possible additional mechanism for clinical benefits. J Cardiovasc Pharinacol 2004; 43: 677-84.
21. Li W, Zhang J, Bottaro DP et al. Identification of serine 643 of protein kinase C-δ as an important autophosphorylation site for its enzymatic activity. J Biol Chem 1997; 272: 24550-5.
22. Murugappan S, Toluc F, Dorsam RT et al. Differential role of protein kinase C isoform in agonist-induced dense granule secretion in human platelets. J Biol Chem 2004; 279: 2360-7.
23. Santucci A, Ferri C, Luparini RL et al. Effect of angiotensin converting enzyme inhibition on platelet angiotensin II content. Am J Med 1988; 84 (Suppl 3A): 119-21.
24. Motley ED, Eguchi K, Gardner C et al. Insulin-induced Akt activation is inhibited by angiotensin II in the vasculature through protein kinase C-α. Hypertension 2003; 41: 775-80.
25. Ishii K, Takekoshi K, Shibuya S et al. Angiotensin subtype-2 receptor (AT2) negatively regulates subtype-1 receptor (AT1) in signal transduction pathways in cultured porcine adrenal medullary chromaffin cells. J Hypertension 2001; 19: 1991-9.
26. Horiuchi M, Hayashida W, Akishita M et al. Stimulation of different subtypes of angiotensin II receptors, AT1 and AT2 receptors, regulates STAT activation by negative crosstalk. Circ Res 1999; 84: 876-82.
27. Huang X-C, Richards EM, Simmers C. Mitogen-activated protein kinases in rat brain neuronal cultures are activated by angiotensin II type1 receptors and inhibited by angiotensin II type2 receptors. J Biol Chem 1996; 271: 15635-41.
28. Kumar V, Knowle D, Gavini N et al. Identification of the region of AT2 receptor needed for inhibition of the AT1 receptor-mediated inositol 1,4,5-triphosphate generation. FEBS Lett 2002; 532: 379-86.
29. Miura S, Karnik SS. Angiotensin II type1 and type2 receptors bind angiotensin II through different types of epitope recognition. J Hypertension 1999; 17: 397-404.
30. 2+-induced α- and dense-core granule secretion in platelets. J Biol Chem 2001; 276: 39379-85.
31. The ACCESS Study Group. The ACCESS study. Evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke 2003; 34: 1699-703.